These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24399039)

  • 1. Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.
    Peleg R; Bobilev D; Priel E
    Int J Oncol; 2014 Mar; 44(3):934-42. PubMed ID: 24399039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
    Bendetz-Nezer S; Gazit A; Priel E
    Mol Pharmacol; 2004 Sep; 66(3):627-34. PubMed ID: 15322255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
    Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
    BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
    Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
    Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action.
    Aflalo E; Iftach S; Segal S; Gazit A; Priel E
    Cancer Res; 1994 Oct; 54(19):5138-42. PubMed ID: 7923131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycoplasma fermentans inhibits the activity of cellular DNA topoisomerase I by activation of PARP1 and alters the efficacy of its anti-cancer inhibitor.
    Afriat R; Horowitz S; Priel E
    PLoS One; 2013; 8(8):e72377. PubMed ID: 24013388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
    Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
    Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-Arylisoquinolines as novel topoisomerase I inhibitors.
    Khadka DB; Cho WJ
    Bioorg Med Chem; 2011 Jan; 19(2):724-34. PubMed ID: 21095131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects.
    Reuveni D; Halperin D; Shalit I; Priel E; Fabian I
    Biochem Pharmacol; 2008 Mar; 75(6):1272-81. PubMed ID: 18191106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
    Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
    Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzo[b]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells.
    Jun KY; Park SE; Liang JL; Jahng Y; Kwon Y
    ChemMedChem; 2015 May; 10(5):827-35. PubMed ID: 25809558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.
    Gokduman K
    Curr Drug Targets; 2016; 17(16):1928-1939. PubMed ID: 27138759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage.
    Holden JA; Wall ME; Wani MC; Manikumar G
    Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
    Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
    Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxic activity of a topoisomerase-I inhibitor, camptothecin, in cultured cerebellar granule neurons.
    Uday Bhanu M; Kondapi AK
    Neurotoxicology; 2010 Dec; 31(6):730-7. PubMed ID: 20600288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
    Dragowska WH; Verreault M; Yapp DT; Warburton C; Edwards L; Ramsay EC; Huxham LA; Minchinton AI; Gelmon K; Bally MB
    Breast Cancer Res Treat; 2007 Dec; 106(3):319-31. PubMed ID: 17347776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.